Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px
Document › Details

BioNTech AG. (9/1/14). "Press Release: Sierk Pötting to Be the New CFO (Chief Financial Officer) of BioNTech Group". Mainz.

Organisations Organisation BioNTech AG
  Group BioNTech (Group)
  Organisation 2 Sandoz (division of Novartis)
  Group Novartis (Group)
Products Product cancer immunotherapy (immuno-oncology, I-O)
  Product 2 cancer test
  Index term 2 BioNTech–Strüngmann Group: investment, –200905– existing investor AT Impf GmbH
Persons Person Pötting, Sierk (BioNTech 201409– CFO before Sandoz Inc/Novartis + McKinsey)
  Person 2 Jeggle, Helmut (STRÜNGMANN Group + before Hexal + scine 2009 Apceth Managing Director CFO)
     


Mainz biopharmaceutical company BioNTech AG has announced that as of September 1, 2014 Mr. Sierk Pötting will join the management team of BioNTech AG as CFO (Chief Financial Officer), succeeding former CFO Mr. Michael Kring.

Sierk Pötting draws on many years of experience. After completing his degree and postdoctoral work in quantum physics, he began his career as a consultant with the company McKinsey before moving over to work with Novartis. For the past several years, Mr. Pötting has served as CFO and Vice President at Sandoz, Inc. in the USA.

"In my view, BioNTech is one of today's most exciting cancer research groups using integrated diagnostic and immunotherapeutic technologies. I am thrilled to have the opportunity to join this company on its journey to the future," explained Sierk Pötting.
Helmut Jeggle, chair of the supervisory board at BioNTech AG, commented: "We are very pleased to strengthen our management team with someone with his background and look forward to working with Mr. Pötting. The timing of his joining BioNTech is perfect for the company's development - Sierk will help us position the company strongly for the long term."

Mr. Michael Kring has made a significant contribution to the establishment of the BioNTech group since 2009 - first as a consultant and since 2010 as CFO. It is planned that he will remain with the company until the end of 2014 as a member of the board at BioNTech AG.

Prof. Ugur Sahin, board member, added: "I would like to warmly thank Michael Kring for his excellent work. Michael has made a very important contribution to the development of the company.

"I am looking forward to working together with Sierk Pötting, whose expertise and many years of experience in the industry will benefit the future of BioNTech."

   
Record changed: 2017-04-02

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px

More documents for BioNTech (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top